Literature DB >> 20510274

Opportunities afforded by new drugs for tuberculosis.

Gavin J Churchyard, Gerald Friedland, Katherine Fielding, Edward Nardell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20510274     DOI： 10.1016/S1473-3099(10)70095-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  2 in total

1.  Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.

Authors:  Amber Kunkel; Forrest W Crawford; James Shepherd; Ted Cohen
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

2.  Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.

Authors:  Harriet L Mills; Ted Cohen; Caroline Colijn
Journal:  Sci Transl Med       Date:  2013-04-10       Impact factor: 17.956
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.